WO2005020996A1 - リピド・リッチ・プラークの安定化方法及び破裂予防方法 - Google Patents
リピド・リッチ・プラークの安定化方法及び破裂予防方法 Download PDFInfo
- Publication number
- WO2005020996A1 WO2005020996A1 PCT/JP2004/011935 JP2004011935W WO2005020996A1 WO 2005020996 A1 WO2005020996 A1 WO 2005020996A1 JP 2004011935 W JP2004011935 W JP 2004011935W WO 2005020996 A1 WO2005020996 A1 WO 2005020996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plaque
- hydrate
- addition salt
- acid addition
- lipid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 150000002632 lipids Chemical class 0.000 title claims abstract description 39
- 230000003405 preventing effect Effects 0.000 title claims abstract description 35
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 230000002265 prevention Effects 0.000 claims abstract description 7
- -1 Benzimidazole-2-ylthio Chemical group 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000007536 Thrombosis Diseases 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 12
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 12
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 11
- 208000007814 Unstable Angina Diseases 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 8
- 230000003449 preventive effect Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 7
- 208000021328 arterial occlusion Diseases 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 5
- 230000009172 bursting Effects 0.000 claims description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 12
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 210000002540 macrophage Anatomy 0.000 abstract description 48
- 102000008186 Collagen Human genes 0.000 abstract description 30
- 108010035532 Collagen Proteins 0.000 abstract description 30
- 229920001436 collagen Polymers 0.000 abstract description 30
- 230000003902 lesion Effects 0.000 abstract description 12
- 230000001603 reducing effect Effects 0.000 abstract description 7
- 230000006641 stabilisation Effects 0.000 abstract description 3
- 238000011105 stabilization Methods 0.000 abstract description 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 2
- VGGMTOYKEDKFLN-UHFFFAOYSA-N 2-[4-[2-(1h-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-n-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)CN1CCN(CCSC=2NC3=CC=CC=C3N=2)CC1 VGGMTOYKEDKFLN-UHFFFAOYSA-N 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 70
- 150000001875 compounds Chemical class 0.000 description 36
- 229940125904 compound 1 Drugs 0.000 description 33
- 235000012000 cholesterol Nutrition 0.000 description 32
- 239000003814 drug Substances 0.000 description 14
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 102000013918 Apolipoproteins E Human genes 0.000 description 9
- 108010025628 Apolipoproteins E Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000011813 knockout mouse model Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 7
- 230000003143 atherosclerotic effect Effects 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000013424 sirius red staining Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000003703 image analysis method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- 241000519995 Stachys sylvatica Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- JVYIBLHBCPSTKF-UHFFFAOYSA-N n-pyridin-3-ylacetamide Chemical compound CC(=O)NC1=CC=CN=C1 JVYIBLHBCPSTKF-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- HDARHUHTZKLJET-UHFFFAOYSA-M sodium;3-(n-ethyl-3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC(OC)=CC(OC)=C1 HDARHUHTZKLJET-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a method for stabilizing lipid 'rich plaque in atherosclerotic lesions and a method for preventing rupture.
- HMG-CoA HMG CoA: 3-hydroxy-3-methyldaritalyl coenzyme A
- IGF-CoA 3-hydroxy-3-methyldaritalyl coenzyme A
- statins Inhibitors
- Cholesterol-lowering therapy using statins has achieved specific results in various arteriosclerotic diseases caused by hyperlipidemia, such as myocardial infarction and cerebral infarction.
- 4S Scandinavian Simvastatin
- other large epidemiological studies for coronary artery disease including acute myocardial infarction, have been shown to be effective in improving survival over five years.
- Statin preparations such as simvastatin (Simvastatin: Patent Document 1) and pravastatin (Pravastatin: Patent Document 2) are effective Even if there is, the rate of improvement in the incidence of coronary artery disease is only about 30%, which is not a satisfactory situation in medical practice.
- the mechanism of statin-induced drug effect is to inhibit the biosynthesis of cholesterol in the body and, at the same time, to increase the expression of LDL receptor due to the decrease in cholesterol in the liver. It is known to cause a reduction in plasma total cholesterol levels. Therefore, there is a problem that LDL cholesterol lowering cannot be fully expected in homozygous and hetero-patients with LDL receptor deficiency such as familial cholesterol (FH).
- plaque which is the main lesion of atherosclerotic lesions, is composed of a lipid core filled with cholesterol and its ester, and a fibrous substance called extracellular matrix.
- lipid-rich plaques which are rich in inflammatory cells such as lipids and macrophages and are covered by a thin fibrous capsule, are also called “unstable plaques"
- the plaque contents are exposed to the bloodstream and promote thrombus formation.
- acute coronary syndrome Acute coronary syndrome: ACS
- acute coronary syndrome such as unstable angina, acute myocardial infarction, sudden ischemic death, etc.
- Non-Patent Document 1 In fact, death from ACS As a result of examining the responsible lesions in the case, it is known that about 75% of the cases were due to thrombus formation accompanying rupture of plaque (Non-Patent Document 2). Focusing on the degree of stenosis of blood vessels, that is, the size of plaque, it was revealed that most of the lesions responsible for myocardial infarction were vascular sites with a stenosis rate of less than 50% (non-patent Reference 2). This suggests that the cause of plaque rupture depends on the quality, not the size, of the plaque.
- asylchoenzyme A cholesterol O-acyltransferase (ACAT) inhibitor has attracted attention as a cholesterol-lowering drug having a different mechanism of action from statins.
- ACAT cholesterol O-acyltransferase
- Patent Document 4 discloses an ACAT inhibitor as a plaque regression agent
- Patent Document 5 discloses a macrophage in plaque.
- ACAT inhibitors have been disclosed that result in reduced accumulation as well as reduced expression of MMPs.
- Non-Patent Document 6 the increase or decrease of fibrous collagen (Non-Patent Document 6), which is one of the important factors contributing to plaque stability, has been reported. What are you touching?
- the compound (abashimibe, hereinafter referred to as CI-1011) examined in this study shows a plaque shrinkage effect, but there is no finding suggesting stabilization such as an increase in fibrous collagen.
- Patent Document 1 US Patent No. 4,444,784
- Patent Document 2 US Patent No. 4,346,227
- Patent Document 3 US Patent No. 5,177,080
- Patent Document 4 Japanese Patent Publication No. 2002-255808
- Patent Document 5 International Publication No.WO01Z034127
- Non-Patent Document 1 N. Engl. J. Med.326 (4): 242-50.1992
- Non-Patent Document 2 Circulation 92 (3): 657-71. 1995
- Non-Patent Document 3 Ann.N.Y.Acad.Sci. 902: 140-52.2000
- Non-Patent Document 4 Exp.Opin.Invest.Drugs 4: 353-387.1995
- Non-Patent Document 5 Drug Discovery Today 3: 19-25.1998
- Non-Patent Document 6 Circ. Res. 86: 101-8.2000
- macrophage-selective ACAT inhibitor and the method for preparing them are disclosed in WO-A-W098Z54153, which are incorporated herein by reference. Be incorporated. Uses of the disclosed compounds are in the treatment of hypercholesterolemia and atherosclerosis, as well as macrophage (selective) foaming No description is given of the drug, but no description of the plaque stabilizing effect.
- the present invention provides a method for treating lipids in atherosclerotic lesions, which comprises administering an effective amount of the compound or an acid addition salt thereof or a hydrate thereof to a patient having lipid 'rich' plaque.
- An object of the present invention is to provide a method for stabilizing 'rich' plaque and a method for preventing rupture.
- the present invention also provides a stabilizer for lipid “rich” plaques and an agent for preventing rupture, comprising a compound or an acid addition salt thereof or a hydrate thereof as an active ingredient.
- the present invention also provides a pharmaceutical composition having a lipid 'rich' plaque stabilizing action, comprising a compound or an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier. It is.
- the present invention also provides a use of Compound 1, or an acid addition salt thereof or a hydrate thereof for producing a lipid'-rich plaque stabilizing agent and an agent for preventing rupture thereof. is there.
- the present invention relates to a method for preparing an effective amount of a compound, an acid addition salt thereof, or a hydrate thereof,
- the present invention provides an agent for preventing thrombus formation accompanying rupture of plaque, comprising a compound, an acid addition salt thereof or a hydrate thereof as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising a compound or an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier and having an action of preventing thrombus formation accompanying rupture of plaque. Is provided. The present invention also provides the use of a compound, an acid addition salt thereof, or a hydrate thereof for producing a preparation for preventing thrombus formation accompanying rupture of plaque.
- the present invention provides a method for preventing acute coronary artery syndrome, which comprises administering an effective amount of a compound, an acid addition salt thereof, or a hydrate thereof to a patient having lipid 'rich plaque. Z or a method of treatment.
- the present invention also provides an agent for preventing and / or treating acute coronary syndrome, comprising a compound or an acid addition salt thereof or a hydrate thereof as an active ingredient.
- the present invention also provides an acute coronary art comprising a compound or an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier. It is intended to provide a pharmaceutical composition having a preventive and / or therapeutic effect on arterial syndrome.
- the present invention also provides the use of a compound or an acid addition salt thereof or a hydrate thereof for the manufacture of a preparation for the prevention and / or treatment of acute coronary syndrome.
- the present invention provides an effective amount of the compound or an acid addition salt thereof or a hydrate thereof.
- the present invention provides a method for preventing and / or treating acute myocardial infarction, which is administered to a patient having Lipid-rich plaque.
- the present invention also provides a preventive and / or therapeutic agent for acute myocardial infarction comprising a compound or an acid addition salt thereof or a hydrate thereof as an active ingredient.
- the present invention provides a pharmaceutical composition having a prophylactic and / or therapeutic effect on acute myocardial infarction, comprising a compound or an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier.
- the present invention also provides the use of a compound or an acid addition salt thereof or a hydrate thereof for the manufacture of a preparation for the prevention and / or treatment of acute myocardial infarction.
- the present invention also provides a method for preventing unstable angina pectoris, which comprises administering an effective amount of a compound or an acid addition salt thereof or a hydrate thereof to a patient having lipid 'rich plaque. And Z or treatment methods. Further, the present invention provides a preventive and / or therapeutic agent for unstable angina pectoris, comprising a compound or an acid addition salt thereof or a hydrate thereof as an active ingredient. Further, the present invention relates to a medicament comprising a compound or an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier, which has a preventive and / or therapeutic effect on unstable angina pectoris. It provides a composition. The present invention also provides the use of a compound or an acid addition salt thereof or a hydrate thereof for the preparation of a preparation for the prevention and / or treatment of unstable angina pectoris.
- the present invention provides a method for preventing peripheral arterial occlusion, which comprises administering an effective amount of a compound, an acid addition salt thereof, or a hydrate thereof to a patient having lipid'rich plaque. Z or a method of treatment.
- the present invention also provides a preventive and / or therapeutic agent for peripheral arterial occlusion, comprising a compound or an acid addition salt thereof or a hydrate thereof as an active ingredient.
- the present invention also relates to a peripheral artery comprising a compound or an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier. It is intended to provide a pharmaceutical composition having a prophylactic and / or therapeutic effect on obstruction.
- the present invention also provides use of Compound 1, or an acid addition salt thereof or a hydrate thereof for the manufacture of a preparation for the prevention and / or treatment of peripheral arterial occlusion.
- Figure 1 shows the results of oral administration of compound l (100 mg / kg), CI-1011 (100 mg / kg) or a solvent twice a day for 12 weeks to male ApoE (ApoE: ApoE) knockout mice.
- FIG. 4 is a view showing the total cholesterol concentration in plasma.
- FIG. 2 shows the results of oral administration of compound l (100 mg / kg), CI-1011 (100 mg / kg) or a solvent twice a day for 12 weeks to male apo E knockout mice
- FIG. 2 is a view showing a plaque cross-sectional area measured by staining a head specimen with Victoria Blue HE (HE: hematoxylin and eosin).
- Victoria Blue HE hematoxylin and eosin
- Figure 3 shows the results of oral administration of compound l (100 mg / kg), CI-1011 (100 mg / kg) or a solvent twice a day for 12 weeks to male apo E knockout mice
- FIG. 2 is a view showing the results of Azan (Azan) staining of a head specimen.
- FIG. 4 shows the results of oral administration of compound l (100 mg / kg), CI-1011 (100 mg / kg) or a solvent twice a day for 12 weeks to male apo E knockout mice
- FIG. 4 is a view showing the result of immunophage immunostaining of a head specimen.
- Figure 5 shows the results of oral administration of compound l (100 mg / kg), CI-1011 (100 mg / kg) or a solvent twice a day for 12 weeks to male apo E knockout mice
- FIG. 2 is a view showing the results of staining the head specimen with Sirius Red (Sirius Red: Sirius Red).
- FIG. 6 is a view showing the result of image analysis of a macrophage immunochemically stained specimen at the beginning to determine macrophage occupancy.
- Figure 7 shows the results of oral administration of compound l (100 mg / kg), CI-1011 (100 mg / kg) or a solvent twice a day for 12 weeks to male apo E knockout mice
- FIG. 4 is a diagram showing the results of image analysis of a beginning red silk red stained specimen and determination of collagen occupancy.
- the present inventors examined the effects of administration of an ACAT inhibitor on plasma total cholesterol concentration and vascular lesions using Apo E knockout mice.
- the aortic root was excised and embedded in paraffin to prepare serial sections, which were stained with Victoria bull's hematoxylin and eosin, azan stain, and macrophage immunohistochemistry. Immunostaining (anti-CD 1 lb antibody) and Sirius red staining were performed.
- FIG. 2 shows the results of analyzing the internal elastic plate with an optical microscope using Victoria Blue 'Hematoxylin' eosin stained specimen and specifying the plaque cross-sectional area.
- the vertical axis in FIG. 2 represents the cross-sectional area of the break (mm 2 ).
- the area of the compound 1 administration group was almost the same as that of the control group, and the plaque cross-sectional area was significantly reduced in the CI 1011 administration group.
- the results of Azan staining are shown in FIG.
- the control group consisted mostly of foamy-dangling macrophages that stained pale red on the surface side of the intima, and a small amount of extracellular matrix stained blue in the deep layer.
- many needle-like white spots called cholesterol craft were found in the plaque.
- the plaque cross-sectional area of the compound 1 administration group was different from that of the control group, but the plaque was composed of a small amount of cellular components and many extracellular matrices surrounding it.
- FIG. 4 shows the results of macrophage immunohistochemistry danikyo staining.
- macrophages were sparsely present in the control group, in which macrophages were abundantly observed on the surface side of the plaques, especially in the control group.
- macrophages were abundant in the entire plaque.
- FIG. 5 shows the results of Sirius red staining. As shown in FIG. 5, dense collagen fibers were observed in the entire plaque in the compound 1 administration group as compared with the control group. However, in the CI-1011 administration group, the collagen fibers exerted less force than in the control group.
- FIG. 6 shows the result of calculating the macrophage occupancy in plaques from the image analysis method shown in FIG.
- the vertical axis in FIG. 6 represents the macrophage occupancy (%) in the plaque.
- the macrophage occupancy was significantly reduced in the compound 1 administration group as compared to the control group.
- the CI 1011 administration group showed a significant increase.
- FIG. 7 shows the results of calculating the collagen occupancy in plaques from the image analysis method shown in FIG.
- the vertical axis in FIG. 7 represents the collagen occupancy (%) in the plaque.
- the collagen occupancy was significantly increased in the compound 1 administration group compared to the control group.
- the C 1-1011 administration group showed a decreasing tendency.
- Compound 1 has the effect of reducing the occupancy of macrophages in plaques and increasing the occupancy of collagen without significantly affecting the fluctuation of plasma total cholesterol concentration. There was found. Thus, Compound 1 can increase collagen and at the same time reduce the occupancy of macrophages, stabilize plaques and prevent rupture.
- the present invention relates to a method for stabilizing lipid 'rich plaque and a method for preventing rupture thereof.
- the present invention relates to a method for administering an effective amount of a pharmaceutical composition comprising one or more active ingredients of a compound, an acid addition salt thereof, or a hydrate thereof, to Lipid'Litsch plaque. It is intended to provide a method for stabilizing a lipid 'rich' plaque and a method for preventing rupture, which are characterized by being administered to a patient having the following.
- the present invention provides a lipid 'rich' plaque comprising a compound or an acid addition salt thereof or one or more active ingredients of hydrates thereof, and a pharmaceutically acceptable carrier.
- Compound 1 of the present invention or an acid addition salt thereof, or a hydrate thereof increases lipid-rich black collagen and decreases macrophage occupancy. Can be stabilized, its rupture prevented, and the formation of a thrombus can be prevented. Therefore, the present invention relates to thrombosis due to thrombus formation, acute coronary syndrome, acute myocardial infarction.
- Prophylactic and / or therapeutic agents for various thrombosis-related diseases such as unstable angina, peripheral arterial occlusion, etc.
- pharmaceutical compositions thereof, prophylactic and / or therapeutic methods using the same, and methods for their production Is provided.
- the pharmaceutical composition having a plaque stabilizing effect of the present invention contains Compound 1 of the present invention as an active ingredient, and is an oral or parenteral agent, for example, an oral agent, an injection, or a suppository.
- a pharmaceutically acceptable carrier may be blended as a composition suitable for an administration form, such as an ointment, a patch or the like, and produced by a formulation method known to those skilled in the art.
- an acid addition salt of compound 1 or a hydrate of compound 1 or an acid addition salt thereof can also be used, and the acid addition salt and hydrate can be obtained by a conventional method.
- the acid that forms the acid addition salt includes inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and hydroiodic acid; acetic acid, lactic acid, succinic acid, tartaric acid, malic acid, and maleic acid.
- Organic acids such as acid, fumaric acid, citric acid, ascorbic acid, methanesulfonic acid, besylic acid, and toluenesulfonic acid.
- Compound 1 of the present invention, or an acid addition salt thereof or a hydrate thereof may be used alone as an active ingredient, but two or more of these may be mixed and used as an active ingredient. It is easy to use.
- the compound 1, an acid addition salt thereof or a hydrate thereof may be added to an excipient, a binder, a disintegrant, a lubricant,
- an excipient e.g., lactose, sucrose, sodium salt, glucose, starch, calcium carbonate, kaolin, and microcrystals. Cellulose, silicic acid, etc.
- binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethinoresenorelose, hydroxypropinoresenorelose, hydroxypropinoresarch, methinolle cellulose. , Ethyl cellulose, shellac, calcium phosphate, polybutylpyrrolidone, etc.
- Disintegrants include dry starch, sodium alginate, agar powder, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, monoglyceride stearate, lactose, etc.
- lubricants include purified talc, stearate, borax And flavoring agents such as sucrose, orange peel, citric acid and tartaric acid.
- a flavoring agent for example, a flavoring agent, a buffering agent, a stabilizing agent, a flavoring agent, etc. may be added to the compound 1, an acid addition salt thereof or a hydrate thereof as required.
- oral liquids, syrups, elixirs and the like can be produced by a conventional method.
- examples of the flavoring agent include those described above.
- Preferred buffers include sodium citrate and the like.
- examples of potentiating agents include tragacanth, gum arabic, and gelatin.
- the compound 1, its acid addition salt or a hydrate thereof may be added, if necessary, with a pH adjuster, a buffer, a stabilizer, an isotonic agent, and a topical agent.
- a pH adjuster By adding an anesthetic or the like, a subcutaneous, intramuscular or intravenous injection can be produced by a conventional method.
- the pH adjusting agent and the buffer include sodium citrate, sodium acetate, sodium phosphate and the like.
- the stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, thiolactic acid and the like.
- Local anesthetics include proforce hydrochloride, lidocaine hydrochloride and the like.
- the tonicity agent include sodium salt sodium, glucose and the like.
- the pharmaceutical composition having a plaque stabilizing effect of the present invention obtained by force can be used to stabilize plaque in atherosclerotic lesions, prevent thrombus formation due to plaque rupture, prevent acute coronary syndrome, and It is effective in preventing or treating Z or treatment, acute myocardial infarction, or preventing or treating acute myocardial infarction, preventing or treating unstable angina pectoris, preventing or treating peripheral arterial occlusion.
- the dose of the pharmaceutical composition having a plaque stabilizing effect of the present invention varies depending on the patient's body weight, age, sex, symptoms, administration form, number of administrations, and the like. It is preferable to administer 0.01 to 1000 mg, preferably 0.1 to 100 mg of Compound 1, its acid addition salt or hydrate thereof orally or parenterally in one or several divided doses per day. preferable.
- Compound 1 (Example 32 in International Publication WO098Z54153) and CI-1011 as a comparative drug (Example 5 in International Publication WO94Z26702) were synthesized according to the methods described in the respective publications. Both Compound 1 and CI 1011 are dissolved (compound 1) or suspended (CI 1011) in 0.5% methylcellulose (MC) aqueous solution, and the dose of 100 mg / kg and the total administration volume is 0. It was prepared to be 1 mL and used. Note that a 0.5% aqueous solution of methylcellulose (MC) as a solvent was used for a control group (a group to which no drug was administered). The prepared drug solution was orally administered twice a day and continued for 12 weeks (up to the age of 20 weeks) (total of 3 groups, 15 patients in each group).
- MC methylcellulose
- mice were fasted. The next morning, the abdomen was opened under anesthesia with pentobarbital sodium to expose the abdominal vena cava, and 1 ml of blood was collected. The collected blood was centrifuged at 3000 rpm for 15 minutes to collect plasma, and the total cholesterol concentration in the plasma was measured by cholesterol E test (cholesterol oxidase'DAOS method).
- thoracotomy After blood collection, thoracotomy is performed, a 20-G injection needle is punctured from the apex of the heart with physiological saline, and 4% paraformaldehyde is perfused with saline at a perfusion pressure of 120 cmH 2 O for about 5 minutes.
- the heart and the thoracic aorta were collected and immersed and fixed in the same fixation solution for at least one day. Thereafter, aortic sinus (origin of the aorta) was cut out and embedded in paraffin.
- FIG. 1 shows the total cholesterol concentration in plasma of each group.
- the total cholesterol concentration in plasma was 641.8 ⁇ 23.Omg / dL
- the total cholesterol concentration in plasma was 535.0 ⁇ 22.8 mg / dL. dL, which was significant (P ⁇ 0.01) but showed a weak lowering effect.
- the total cholesterol concentration in plasma was 360.3 ⁇ 19.4 mg / dL, which was significant (P ⁇ 0.01) and significantly lower than that of Compound 1. showed that. From the above results, it was found that the effect of lowering the plasma total cholesterol concentration was observed in any of the tested drugs, and that the effect was remarkable in the 100 mg / kg group of CI1011.
- Figure 2 shows the plaque cross-sectional area measured with Victoria Blue 'hematoxylin' eosin stained specimens of each group. Plaque sectional area 0. 23 ⁇ 0 of the control group. Is whereas a 03Mm 2, the 100 mg / kg administration group of compound 1, plaque cross-sectional area is 0. 22 ⁇ 0. 03mm 2, change There was no. In contrast, the plaque cross-sectional area was 0.09 ⁇ 0 in the 100 mg / kg group of CI-1011. 0.01 mm 2 , and the plaque cross-sectional area reducing effect was strong and significant (P 0.01) as compared with Compound 1. From the above results, it was found that the plaque cross-sectional area reducing effect, that is, the plaque reducing effect was observed in the CI-1011 100 mg / kg administration group.
- FIGS. 3 to 5 The results of Azan staining, macrophage immunohistochemical staining and Sirius red staining are shown in FIGS. 3 to 5, respectively.
- the lower part in the figure corresponds to the outer membrane side.
- the control group consisted mostly of foamed macrophages that stained mostly pale red on the surface side of the intima, and the extracellular matrix that stained blue slightly in the deep layer. Admitted. In addition, many needle-like white spots called cholesterol kraft were found in the plaque. In contrast, in the 100 mg / kg compound 1 group, the plaque cross-sectional area was as strong as the control group, but the plaque also had a small amount of cellular components and many extracellular matrix forces surrounding it. . In the C to 1011 treatment group, the cross-sectional area was smaller than that in the control group. Most of the force plaque was composed of macrophages, and the extracellular matrix was poor.
- FIG. 4 shows the results of the macrophage immunohistochemistry danikyo staining.
- macrophages were particularly abundantly observed on the surface side of the plaque. Macrophages were only sparsely present in the compound 1 administration group.
- macrophages were abundant in the entire plaque.
- FIG. 5 shows the results of Sirius red staining. As shown in FIG. 5, dense collagen fibers were observed in the entire plaque of the compound 1 administration group as compared with the control group. However, the CI 1011 administration group had less collagen fibers than the control group.
- FIG. 6 shows the results of calculating the occupancy rate of macrophages in plaques from the image analysis method shown in FIG.
- the macrophage occupancy was 33.2 ⁇ 2.2% in the control group, whereas the macrophage occupancy was 20.0 ⁇ 1.7% in the 100 mg / kg administration group of compound 1 (significantly). P was reduced to 0.01).
- the group administered with CI-1011 at 100 mg / kg a significant increase of ⁇ 4.01 ⁇ 2.7% was obtained ( ⁇ 0.01).
- FIG. 7 shows the results of calculating the collagen occupancy in plaques from the image analysis method based on FIG.
- the collagen occupancy was 9.6 ⁇ 1.1% in the control group, and 14.9 ⁇ 1.0% in the 100 mg / kg administration group of compound 1 (significantly). Increased to P (0.05) did.
- the lOOmg / kg group of CI-1011 showed a decreasing trend of 7.0 ⁇ 0.9%.
- the plaque cross-sectional area and histological evaluation were examined.
- CI 1011 showed a decrease in plaque cross-sectional area at a concentration that lowers plasma total cholesterol concentration, that is, although an effect of reducing plaque was observed, it showed an increase in macrophage occupancy and a decrease in collagen occupancy.
- Compound 1 only slightly reduced the total cholesterol concentration in plasma and showed no plaque-reducing effect, but showed a decrease in macrophage occupancy and an increase in collagen occupancy. It has been found that it has a stable function of a stable black.
- lipid 'rich plaque in an atherosclerotic lesion and a method for preventing rupture.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002535920A CA2535920C (en) | 2003-08-29 | 2004-08-19 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
NZ544803A NZ544803A (en) | 2003-08-29 | 2004-08-19 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
EP04771896A EP1666038A4 (en) | 2003-08-29 | 2004-08-19 | METHOD FOR STABILIZING A LIPID-RICH PLATE AND METHOD FOR PREVENTING THE BREAKAGE OF THE PLATE |
US10/569,642 US7884106B2 (en) | 2003-08-29 | 2004-08-19 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
AU2004267972A AU2004267972B2 (en) | 2003-08-29 | 2004-08-19 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
JP2005513426A JPWO2005020996A1 (ja) | 2003-08-29 | 2004-08-19 | リピド・リッチ・プラークの安定化方法及び破裂予防方法 |
US12/857,671 US20110015206A1 (en) | 2003-08-29 | 2010-08-17 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49861003P | 2003-08-29 | 2003-08-29 | |
US60/498,610 | 2003-08-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/857,671 Division US20110015206A1 (en) | 2003-08-29 | 2010-08-17 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005020996A1 true WO2005020996A1 (ja) | 2005-03-10 |
Family
ID=34272704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/011935 WO2005020996A1 (ja) | 2003-08-29 | 2004-08-19 | リピド・リッチ・プラークの安定化方法及び破裂予防方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7884106B2 (ja) |
EP (1) | EP1666038A4 (ja) |
JP (1) | JPWO2005020996A1 (ja) |
KR (1) | KR20060111898A (ja) |
CN (1) | CN100438872C (ja) |
AU (1) | AU2004267972B2 (ja) |
CA (1) | CA2535920C (ja) |
NZ (1) | NZ544803A (ja) |
RU (1) | RU2358734C2 (ja) |
WO (1) | WO2005020996A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011081117A1 (ja) | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用固形医薬組成物 |
WO2011081118A1 (ja) | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用医薬組成物 |
WO2011145340A1 (ja) | 2010-05-19 | 2011-11-24 | 興和株式会社 | 非アルコール性脂肪性肝炎の予防及び/又は治療剤 |
WO2011161964A1 (ja) * | 2010-06-24 | 2011-12-29 | 興和株式会社 | Acat阻害剤を有効成分とするインスリン抵抗性改善剤 |
JP2017015550A (ja) * | 2015-07-01 | 2017-01-19 | 公益財団法人ヒューマンサイエンス振興財団 | 2重染色キット |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ544803A (en) * | 2003-08-29 | 2009-11-27 | Kowa Co | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
EP1981493A4 (en) * | 2006-11-13 | 2009-11-11 | Sosei Co Ltd | ACAT HEMMER AND ITS USE IN PREVENTING OR TREATING FIBROSIS |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
JP6688224B2 (ja) | 2014-01-28 | 2020-04-28 | バック インスティテュート フォー リサーチ オン エイジング | Mdm2を阻害する手段の投与による関節における変形性関節症の処置 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026702A1 (en) * | 1993-05-14 | 1994-11-24 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
WO1998054153A1 (fr) * | 1997-05-26 | 1998-12-03 | Kowa Company, Ltd. | Nouveaux composes de diamine cycliques et medicament contenant ces composes |
WO2003057675A1 (fr) * | 2001-12-28 | 2003-07-17 | Kowa Co., Ltd. | Procedes pour produire des composes de diamine cyclique ou des sels de ceux-ci |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
US5491172A (en) | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
IT1270976B (it) * | 1993-08-06 | 1997-05-26 | Pierrel Spa | Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica, loro uso e composizioni farmaceutiche che li contengono |
BR9611410A (pt) | 1995-11-02 | 1999-01-05 | Warner Lambert Co | Método e composição farmacêutica para regular a concentração de lipídios |
US6969711B2 (en) | 1997-05-26 | 2005-11-29 | Kowa Company, Ltd. | Cyclic diamine compounds and medicine containing the same |
WO2001022962A1 (en) | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
IL149145A0 (en) | 1999-11-05 | 2002-11-10 | Warner Lambert Co | Prevention of plaque rupture by acat inhibitors |
US6974806B2 (en) * | 2000-07-13 | 2005-12-13 | Takeda Pharmaceutical Company Limited | Lipid-rich plaque inhibitors |
JP2002255808A (ja) | 2000-07-13 | 2002-09-11 | Takeda Chem Ind Ltd | リピド・リッチ・プラーク退縮剤 |
PL362244A1 (en) | 2000-09-01 | 2004-10-18 | Sankyo Company, Limited | Medicinal compositions |
AU2003248246A1 (en) | 2002-06-25 | 2004-01-06 | Kyowa Hakko Kogyo Co., Ltd. | Hetero-bicyclic compounds |
MY140618A (en) | 2003-02-28 | 2009-12-31 | Kowa Co | Method for preparing acid addition salts of polyacidic basic compounds |
NZ544803A (en) * | 2003-08-29 | 2009-11-27 | Kowa Co | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
TW200619204A (en) | 2004-12-10 | 2006-06-16 | Kowa Co | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
-
2004
- 2004-08-19 NZ NZ544803A patent/NZ544803A/en not_active IP Right Cessation
- 2004-08-19 EP EP04771896A patent/EP1666038A4/en not_active Withdrawn
- 2004-08-19 RU RU2006110035/14A patent/RU2358734C2/ru not_active IP Right Cessation
- 2004-08-19 CA CA002535920A patent/CA2535920C/en not_active Expired - Fee Related
- 2004-08-19 CN CNB2004800248942A patent/CN100438872C/zh not_active Expired - Fee Related
- 2004-08-19 JP JP2005513426A patent/JPWO2005020996A1/ja not_active Ceased
- 2004-08-19 AU AU2004267972A patent/AU2004267972B2/en not_active Ceased
- 2004-08-19 US US10/569,642 patent/US7884106B2/en not_active Expired - Fee Related
- 2004-08-19 WO PCT/JP2004/011935 patent/WO2005020996A1/ja active Application Filing
- 2004-08-19 KR KR1020067000314A patent/KR20060111898A/ko active IP Right Grant
-
2010
- 2010-08-17 US US12/857,671 patent/US20110015206A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026702A1 (en) * | 1993-05-14 | 1994-11-24 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
WO1998054153A1 (fr) * | 1997-05-26 | 1998-12-03 | Kowa Company, Ltd. | Nouveaux composes de diamine cycliques et medicament contenant ces composes |
WO2003057675A1 (fr) * | 2001-12-28 | 2003-07-17 | Kowa Co., Ltd. | Procedes pour produire des composes de diamine cyclique ou des sels de ceux-ci |
Non-Patent Citations (1)
Title |
---|
See also references of EP1666038A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011081117A1 (ja) | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用固形医薬組成物 |
WO2011081118A1 (ja) | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用医薬組成物 |
WO2011145340A1 (ja) | 2010-05-19 | 2011-11-24 | 興和株式会社 | 非アルコール性脂肪性肝炎の予防及び/又は治療剤 |
JP5800368B2 (ja) * | 2010-05-19 | 2015-10-28 | 興和株式会社 | 非アルコール性脂肪性肝炎の予防及び/又は治療剤 |
WO2011161964A1 (ja) * | 2010-06-24 | 2011-12-29 | 興和株式会社 | Acat阻害剤を有効成分とするインスリン抵抗性改善剤 |
JP2017015550A (ja) * | 2015-07-01 | 2017-01-19 | 公益財団法人ヒューマンサイエンス振興財団 | 2重染色キット |
Also Published As
Publication number | Publication date |
---|---|
RU2006110035A (ru) | 2006-07-27 |
CN1845737A (zh) | 2006-10-11 |
US7884106B2 (en) | 2011-02-08 |
US20110015206A1 (en) | 2011-01-20 |
EP1666038A4 (en) | 2010-10-20 |
EP1666038A1 (en) | 2006-06-07 |
RU2358734C2 (ru) | 2009-06-20 |
KR20060111898A (ko) | 2006-10-30 |
AU2004267972A1 (en) | 2005-03-10 |
JPWO2005020996A1 (ja) | 2007-11-01 |
CA2535920C (en) | 2009-06-23 |
NZ544803A (en) | 2009-11-27 |
CA2535920A1 (en) | 2005-03-10 |
AU2004267972B2 (en) | 2010-07-08 |
US20070004749A1 (en) | 2007-01-04 |
CN100438872C (zh) | 2008-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10449154B2 (en) | Treatment of NASH with Gemcabene | |
US20110015206A1 (en) | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof | |
US5393772A (en) | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation | |
JP4875491B2 (ja) | メトホルミンとスタチンとの組み合わせを含む医薬組成物 | |
EP1894576B1 (en) | Novel triglyceride reducing agent | |
US20110207742A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
WO2002030425A1 (fr) | Medicaments pour la prevention ou le traitement de complications du diabete | |
AU2007336077A1 (en) | New combination for use in the treatment of inflammatory disorders | |
JP2007513991A (ja) | メタボリック症候群の処置のためのスタチンの使用 | |
EP1621210A1 (en) | Adiponectin production enhancer | |
US20130095059A1 (en) | Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model | |
JP2022013721A (ja) | 排尿症状治療剤 | |
JP2005053890A (ja) | アディポネクチン濃度低下及び/又はc反応性蛋白濃度上昇及び/又はil−18濃度上昇に起因する疾患の予防及び/又は治療剤。 | |
JP2011173812A (ja) | 動脈硬化症予防治療剤 | |
JP2006265145A (ja) | 糖尿病性腎症の治療用医薬組成物 | |
WO1998043627A1 (fr) | Medicaments preventifs contre des affections d'ischemie cardiaque |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480024894.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020067000314 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 544803 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005513426 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004267972 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2535920 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007004749 Country of ref document: US Ref document number: 10569642 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2004267972 Country of ref document: AU Date of ref document: 20040819 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004267972 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004771896 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006110035 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004771896 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067000314 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10569642 Country of ref document: US |